¼¼°è ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ - ¾àÁ¦ À¯Çüº°, Åõ¿© °æ·Îº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)
Cytotoxic Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Type; By Route of Administration; By Application ; By Distribution Channel; By Region; Segment Forecast, 2024- 2032
»óǰÄÚµå : 1449247
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 117 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃÖ±Ù Á¶»ç¿¡ µû¸£¸é ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 208¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¼³¹®Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» ÀÚ¼¼È÷ ÆÄ¾ÇÇϰí ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀåÀÇ ¼ºÀåÀº ¿¬±¸ °³¹ß(R&D)ÀÇ »ó´çÇÑ Áøº¸·Î À̾îÁý´Ï´Ù. ²÷ÀÓ¾ø´Â ¿¬±¸°³¹ß ³ë·ÂÀÇ °á°ú, È¿´ÉÀÌ Çâ»óµÇ¾î ºÎÀÛ¿ëÀÌ °æ°¨µÈ ½Å±Ô ¼¼Æ÷µ¶¼º¾àÀÌ µ¿Á¤µÇ°í ÀÖ½À´Ï´Ù. Á¦Á¦¿Í Àü´Þ ±â¼úÀÇ Áøº¸´Â Ä¡·á ´É·ÂÀ» ³ôÀÌ°í ´Ù¾çÇÑ ¾Ï¿¡ ´ëÇÑ Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ Á¦ÈÞ¿¡ ÀÇÇØ °³¹ß±â°£ÀÌ ´ÜÃàµÇ¾î ÃÖ÷´Ü ¼¼Æ÷µ¶¼º¾àÀÌ °³¹ßµÇ¾ú½À´Ï´Ù. ºÐÀÚ Ç¥ÀûÀÇ Áö¼ÓÀûÀÎ ¿¬±¸¿¡ ÀÇÇØ º¸´Ù Á¤È®ÇÏ°í ¸ÂÃã Ä¡·á¹ýÀÇ °³¹ßÀÌ °¡´ÉÇØÁö°í Á¤¹ÐÀÇ·áÀÇ º¯È­¿Í Á¶È­µÇ¾î ¾Ï Ä¡·áÀÇ Áøº¸¿¡ ´ëÇÑ ¾÷°èÀÇ Çå½ÅÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀåÀº ¶ÇÇÑ ¸ÂÃãÇü ÀÇ·áÀÇ »ó½Â°ú ÇÔ²² º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀº °³º° ȯÀÚ °íÀ¯ÀÇ À¯ÀüÀû ¹× ºÐÀÚÀû ÇÁ·ÎÆÄÀÏ¿¡ ¸Â°Ô ¼¼Æ÷µ¶¼º ¾à¹° Ä¡·á¸¦ Á¶ÀýÇÏ´Â °ÍÀÔ´Ï´Ù. °í±Þ ºÐÀÚÁø´Ü°ú À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµÀ» äÅÃÇÔÀ¸·Î½á Á¤È®ÇÑ ¾à¹° ¼±ÅÃ, ºÎÀÛ¿ë ÃÖ¼ÒÈ­, Ä¡·á ¼ºÀû ÃÖÀûÈ­°¡ °¡´ÉÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¸ÂÃãÇü Ä¡·á¿¡ ÅõÀÚÇϰí ÀÖ´Â ±â¾÷Àº ¾ÏÄ¡·á¿¡ À־ÀÇ Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇØ, ½ÃÀåÀÇ ´ëÆøÀûÀÎ ¼ºÀå¿¡ À¯¸®ÇÑ ÀÔÀå¿¡ ÀÖ½À´Ï´Ù.

¿ø°Ý ÀÇ·á ¹× µðÁöÅÐ °Ç°­Àº ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀåÀÇ ºñÁî´Ï½º ±âȸ¸¦ ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á Ç÷§Æû°ú µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ µµÀÔÀº ȯÀÚ °ü¸® ¹× ¾à¹° Åõ¿©¿¡ »õ·Î¿î ±æÀ» ¿­¾îÁÝ´Ï´Ù. ¿ø°Ý Áø´Ü ¹× °¡»ó ¸ð´ÏÅ͸µÀº ¼¼Æ÷ µ¶¼º ¾à¹° Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀ̰í ȯÀÚ¿¡°Ô ±¤¹üÀ§ÇÑ È°µ¿°ú º¹¿ë ¾îµåÈ÷¾î·±½ºÀÇ Çâ»óÀ» º¸ÀåÇÕ´Ï´Ù.

µðÁöÅÐ Çコ ±â¼úÀ» ÅëÇÑ ½Ç½Ã°£ µ¥ÀÌÅÍ ¼öÁýÀ» Ȱ¿ëÇÔÀ¸·Î½á ȯÀÚÀÇ ¹ÝÀÀ¿¡ µû¶ó Ä¡·á °èȹÀ» ¸ÂÃãÈ­ÇÒ ¼ö ÀÖ¾î ¼¼Æ÷µ¶¼º ¾à¹°ÀÇ È¿°ú¸¦ ÃÖÀûÈ­Çϰí Ä¡·á ¼ºÀû Çâ»ó¿¡ ±â¿©ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áøº¸´Â ¶ÇÇÑ °Ç°­ °ü¸® Àü¹®°¡, ȯÀÚ ¹× °£º´ÀÎ °£ÀÇ ÀÇ»ç ¼ÒÅëÀ» ´Ü¼øÈ­ÇÏ°í ¾Ï Ä¡·á¿¡ ´ëÇÑ Çù·ÂÀûÀ̰í ÃæºÐÇÑ Á¤º¸¸¦ ±â¹ÝÀ¸·Î ÇÑ Á¢±Ù¹ýÀ» ÃËÁøÇÕ´Ï´Ù.

¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

2023³â ´ë»ç ±æÇ×Á¦ ºÎ¹®Àº ¼±ÅÃÀû Ÿ°ÙÆÃ°ú ±¤¹üÀ§ÇÑ Àû¿ë¼ºÀ¸·Î ÀÎÇØ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2023³â¿¡´Â ÆíÀǼº°ú ȯÀÚ Á᫐ Á¢±Ù ¹æ½ÄÀ¸·Î °æ±¸ ºÎ¹®ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2023³â À¯¹æ¾Ï ºÐ¾ß´Â ¼¼°è À¯¹æ¾Ï ȯÀÚ Áõ°¡¿Í º´¿ë ¿ä¹ý¿¡¼­ÀÇ »ç¿ëÀ¸·Î Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2023³â, º´¿ø ¾à±¹ ºÎ¹®Àº °Ç°­ °ü¸® ±â°ü ³»¿¡¼­ ȯÀÚ°¡ ½±°Ô Á¢±ÙÇÒ ¼ö Àֱ⠶§¹®¿¡ Å« ÆÇ¸Å Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2023³â¿¡´Â ¾Ï ȯÀÚ Áõ°¡¿Í °í·ÉÈ­·Î ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°è ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°è ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : ¾àÁ¦À¯Çüº°

Á¦6Àå ¼¼°è ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : ¿ëµµº°

Á¦7Àå ¼¼°è ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : Åõ¿©°æ·Îº°

Á¦8Àå ¼¼°è ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : À¯Åë ä³Îº°

Á¦9Àå ¼¼°è ¼¼Æ÷ µ¶¼º ¾à¹° ½ÃÀå : Áö¿ªº°

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Cytotoxic Drugs market size is expected to reach USD 20.80 billion by 2032, according to a new study by Polaris Market Research. The report "Cytotoxic Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Type; By Route of Administration; By Application (Lung Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Others); By Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of the cytotoxic drugs market is driven by substantial progress in research and development (R&D). Persistent R&D endeavors result in the identification of novel cytotoxic drugs with increased effectiveness and reduced side effects. Advances in formulations and delivery techniques augment therapeutic capabilities, expanding the array of treatment choices for diverse cancers. Partnerships between pharmaceutical companies and research institutions havetened development timelines, unveiling state-of-the-art cytotoxic drugs. Continuous investigation into molecular targets enables the development of more accurate, individualized therapies, harmonizing with the changing landscape of precision medicine and emphasizing the industry's dedication to progressing cancer treatment.

The cytotoxic drugs market is also transforming with the rise of personalized medicine. This innovative approach tailors cytotoxic drug treatments to individual patient's unique genetic and molecular profiles. Employing advanced molecular diagnostics and genetic profiling enables precise drug selection, minimizing adverse effects, and optimizing therapeutic outcomes. Companies investing in these personalized therapies are well-positioned for substantial market growth, meeting the increasing demand for precision medicine in cancer treatment.

Telemedicine and digital health are transforming opportunities within the cytotoxic drugs market. The incorporation of telemedicine platforms and digital health solutions creates fresh pathways for patient care and drug administration. Distant consultations and virtual monitoring increase the accessibility of cytotoxic drug treatments, ensuring a wider patient outreach and improved adherence.

Utilizing real-time data collection via digital health technologies allows for customized treatment plans based on patient responses, optimizing the effectiveness of cytotoxic drugs and contributing to enhanced outcomes. These advancements also simplify communication among healthcare professionals, patients, and caregivers, promoting a collaborative and informed approach to cancer treatment.

Cytotoxic Drugs Market Report Highlights

In 2023, the antimetabolites segment accounted for significant market share owing to selective targeting, and broad applicability.

In 2023, the oral segment accounted for significant market share owing to convenience and patient-centric approach.

In 2023, the breast cancer segment held significant revenue share owing to rise in cases of breast cancer across the world, and use in combination therapies.

In 2023, the hospital pharmacy segment held significant revenue share owing to easy access for patients within healthcare institutions.

In 2023, North America region dominated the global market due to rising cancer cases and an aging population.

The market is highly competitive owing to the existence of market players with a global presence, including AstraZeneca, Baxter, Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., and Pfizer among others.

Polaris Market Research has segmented the Cytotoxic Drugs market report based on drug type, route of administration, application, distribution channel, and region:

Cytotoxic Drugs, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

Cytotoxic Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Cytotoxic Drugs, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Cytotoxic Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

Cytotoxic Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Cytotoxic Drugs Market Insights

5. Global Cytotoxic Drugs Market, by Drug Type

6. Global Cytotoxic Drugs Market, by Application

7. Global Cytotoxic Drugs Market, by Route of Administration

8. Global Cytotoxic Drugs Market, by Distribution Channel

9. Global Cytotoxic Drugs Market, by Geography

10. Competitive Landscape

11. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â